Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07762755

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07762755
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07762755. Randomized; single masking; primary purpose treatment. Start 2026-08-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT
Acronym
IPE-NaF
Condition
Hyperlipidaemia
Condition
Hypertriglyceridaemia
Condition
Coronary Atherosclerosis
Intervention (Drug)
icosapent ethyl (IPE)
Intervention (Drug)
Standard LDL-C-Lowering Therapy
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)
Collaborator
Beijing Anzhen Hospital (class: other)
Collaborator
Beijing Chao Yang Hospital (class: other)
Collaborator
Beijing Municipal Health Commission (class: other government)

Record details

Record id
cardio:ct-nct07762755
Content hash
bfaa247177e3489de8a9d1f7a00b877d11e60328c1046f8ee32e4537c3a6405d